作为全球糖尿病与肥胖症治疗领域的绝对巨头,诺和诺德曾凭借司美格鲁肽系列产品缔造医药行业的增长神话,市值一度登顶欧洲上市公司榜首。然而进入2026年,这家丹麦制药巨头却遭遇开年暴击:明星产品司美格鲁肽仅以4亿美元之差痛失“全球药王”宝座,美国市场突现低价“山寨”司美格鲁肽搅局,口服减肥药被FDA指为虚假宣传,叠加专利悬崖倒计时的大背景,诺和诺德全球防线告急。 财报对决司美格鲁肽惜败药王 2026...
Source Link作为全球糖尿病与肥胖症治疗领域的绝对巨头,诺和诺德曾凭借司美格鲁肽系列产品缔造医药行业的增长神话,市值一度登顶欧洲上市公司榜首。然而进入2026年,这家丹麦制药巨头却遭遇开年暴击:明星产品司美格鲁肽仅以4亿美元之差痛失“全球药王”宝座,美国市场突现低价“山寨”司美格鲁肽搅局,口服减肥药被FDA指为虚假宣传,叠加专利悬崖倒计时的大背景,诺和诺德全球防线告急。 财报对决司美格鲁肽惜败药王 2026...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.